Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
US11149077B2 · kind B2 · utility
1Cited by
73References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 10, 2019 |
| Grant date | Oct 19, 2021 |
| Priority date | — |
| Expiry date | Jan 22, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC40B40/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides innovative proteins that bind to insulin-like growth factor-I receptor (IGF-IR), as well as other important proteins. The invention also provides innovative proteins in pharmaceutical preparations and derivatives of such proteins and the uses of same in diagnostic, research and therapeutic applications. The invention further provides cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.